Publication Name	World Journal of Diabetes
Manuscript ID	47209
Country	United States

Received	2019-03-11 09:18
Peer-Review Started	2019-03-12 01:17
To Make the First Decision	2019-05-09 00:22
Return for Revision	2019-05-09 02:00
Revised	2019-05-13 07:26
Second Decision	2019-05-13 11:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2019-05-14 01:32
Articles in Press	2019-05-14 01:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-05-14 09:50
Publish the Manuscript Online	2019-05-15 10:17

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Management of diabetic dyslipidemia: An update
Manuscript Source	Invited Manuscript
All Author List	Ishwarlal Jialal and Gurdeep Singh
Funding Agency and Grant Number
Corresponding Author	Ishwarlal Jialal, MD, PhD, Professor, California North-state University College of Medicine, VA Medical Center, Mather, 9700 West Taron Drive, Elk Grove, CA 95757, United States. ishwarlal.jialal@cnsu.edu
Key Words	Diabetes; Dyslipidemia; Statins; Atherosclerosis; Ezetimibe
Core Tip	Atherosclerotic cardiovascular disease (ASCVD) is the major cause of mortality in diabetes. Low-density lipoprotein (LDL)-cholesterol lowering with statins reduce ASCVD and is the mainstay of therapy. Also, both ezetimibe and PCSK9 inhibitors are useful strategies when statins cannot be tolerated or the LDL-cholesterol goal is not achieved.
Publish Date	2019-05-15 10:17
Citation	Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabetes 2019; 10(5): 280-290
URL	https://www.wjgnet.com/1948-9358/full/v10/i5/280.htm
DOI	https://dx.doi.org/10.4239/wjd.v10.i5.280

Full Article (PDF)	WJD-10-280.pdf
Full Article (Word)	WJD-10-280.docx
Manuscript File	47209-Review.docx
Answering Reviewers	47209-Answering reviewers.pdf
Audio Core Tip	47209-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	47209-Conflict-of-interest statement.pdf
Copyright License Agreement	47209-Copyright license agreement.pdf
Peer-review Report	47209-Peer-review(s).pdf
Scientific Misconduct Check	47209-Scientific misconduct check.pdf
Scientific Editor Work List	47209-Scientific editor work list.pdf
CrossCheck Report	47209-CrossCheck report.pdf